Immunohistochemical testing of GISTs using CD117 markers: the UK NEQAS ICC & ISH external quality assessment data show significant differences in the performance of methods in regular use - Takeaways - MDSpire

Immunohistochemical testing of GISTs using CD117 markers: the UK NEQAS ICC & ISH external quality assessment data show significant differences in the performance of methods in regular use

  • By

  • Andrew Dodson

  • Suzanne Parry

  • July 17, 2026

Share

  • 1

    CD117 is a critical marker for diagnosing gastrointestinal stromal tumors (GISTs), with mutations in the KIT gene driving tumorigenesis.

  • 2

    The UK NEQAS ICC & ISH conducted 20 runs of an external quality assessment program for CD117 expression in GIST from May 2020 to May 2025.

  • 3

    Out of 2,656 submissions, 99.5% received a quality score indicating acceptable stain quality, with only 0.5% failing.

  • 4

    The polyclonal antiserum from Agilent Dako produced the highest quality staining, while Clone 9.7 from Roche Diagnostics was statistically inferior.

  • 5

    A strong trend was observed for increasing proportions of submissions achieving good/excellent quality scores over time.

Original Source(s)

Immunohistochemical testing of GISTs using CD117 markers: the UK NEQAS ICC & ISH external quality assessment data show significant differences in the performance of methods in regular use

  • by Andrew Dodson, Suzanne Parry

  • July 17, 2026

Related Content

The dual role of parasites and parasite-derived products in cancer biology: a systematic review of in vitro and in vivo evidence

Correction: Crosstalk between abnormal TSHR signaling activation and PTEN/PI3K in the dedifferentiation of thyroid cancer cells

Intravascular large B-cell lymphoma masked by multinodular goiter of the thyroid: a case report and diagnostic pitfall